Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial
Open Access
- 15 March 2020
- journal article
- research article
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 8 (1), e000943
- https://doi.org/10.1136/bmjdrc-2019-000943
Abstract
Background High-density lipoprotein (HDL) levels are inversely associated with cardiovascular risk. Cholesteryl ester transfer protein inhibition with evacetrapib results in a marked increase in HDL and reduction in low-density lipoprotein (LDL) levels. We evaluated the impact of treatment with evacetrapib versus placebo in the subset of 8236 patients with diabetes mellitus (DM) enrolled in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High Risk for Vascular Outcomes trial. Methods and results Time to first occurrence of any component of the primary composite endpoint of cardiovascular death, myocardial infarction, stroke, revascularization, and hospitalization for unstable angina was compared among patients with DM randomized to treatment with evacetrapib (n=4127) or placebo (n=4109) over a median of 26 months of follow-up. The mean baseline LDL at initiation was 80 mg/dL with a mean baseline HDL of 44 mg/dL. In patients with DM, evacetrapib resulted in a 131% mean increase in HDL levels and a 32% mean decrease in LDL at 3 months that was sustained during the course of the trial. At 6 months, hemoglobin A1c (HbA1c) levels were lower with evacetrapib than placebo (7.08% vs 7.15%, p=0.023). Composite event rates were higher in patients with DM than without DM (Kaplan-Meier estimates: 15.2% vs 10.6%, HR 1.46, 95% CI 1.30 to 1.64, pConclusion Despite a favorable increase in HDL, and decreases in LDL and HbA1c levels in patients with DM, we observed no benefits of treatment with evacetrapib on prespecified clinical outcomes in this high-risk population.Keywords
This publication has 43 references indexed in Scilit:
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary SyndromeThe New England Journal of Medicine, 2012
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL CholesterolJAMA, 2011
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific DeathThe New England Journal of Medicine, 2011
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and AtherosclerosisThe New England Journal of Medicine, 2011
- Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial InfarctionCirculation: Cardiovascular Genetics, 2009
- Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysisThe Lancet, 2008
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsThe New England Journal of Medicine, 2007
- HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular EventsThe New England Journal of Medicine, 2007
- High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transportAtherosclerosis, 1996